To investigate a computed tomography (CT)-based multiparameter deep learning-radiomic model (DLRM) for predicting the preoperative tumor budding (TB) grade in patients with rectal cancer. Data from 135 patients with histologically confirmed rectal cancer (85 in the Bd1+2 group and 50 in the Bd3 group) were retrospectively included. Deep learning (DL) features and hand-crafted radiomic (HCR) features were separately extracted and selected from preoperative CT-based extracellular volume (ECV) parameter images and venous-phase images. Six predictive signatures were subsequently constructed from machine learning classification algorithms. Finally, a combined DL and HCR model, the DLRM, was established to predict the TB grade of rectal cancer patients by merging the DL and HCR features from the two image sets. In the training and test cohorts, the AUC values of the DLRM were 0.976 [95% CI: 0.942-0.997] and 0.976 [95% CI: 0.942-1.00], respectively. The DLRM had good output agreement and clinical applicability according to calibration curve analysis and DCA, respectively. The DLRM outperformed the individual DL and HCR signatures in terms of predicting the TB grade of rectal cancer patients (p < 0.05). The DLRM can be used to evaluate the TB grade of rectal cancer patients in a noninvasive manner before surgery, thereby providing support for clinical treatment decision-making for these patients.

Accurate determination of human epidermal growth factor receptor 2 (HER2) expression is critical for guiding targeted therapy in breast cancer. This study aimed to develop and validate a deep learning (DL)-based decision-making visual biomarker system (DM-VBS) for predicting HER2 status using radiomics and DL features derived from magnetic resonance imaging (MRI) and mammography (MG). Radiomics features were extracted from MRI, and DL features were derived from MG. Four submodels were constructed: Model I (MRI-radiomics) and Model III (mammography-DL) for distinguishing HER2-zero/low from HER2-positive cases, and Model II (MRI-radiomics) and Model IV (mammography-DL) for differentiating HER2-zero from HER2-low/positive cases. These submodels were integrated into a XGBoost model for ternary classification of HER2 status. Radiologists assessed imaging features associated with HER2 expression, and model performance was validated using two independent datasets from The Cancer Image Archive. A total of 550 patients were divided into training, internal validation, and external validation cohorts. Models I and III achieved an area under the curve (AUC) of 0.800-0.850 for distinguishing HER2-zero/low from HER2-positive cases, while Models II and IV demonstrated AUC values of 0.793-0.847 for differentiating HER2-zero from HER2-low/positive cases. The DM-VBS achieved average accuracy of 85.42%, 80.4%, and 89.68% for HER2-zero, -low, and -positive patients in the validation cohorts, respectively. Imaging features such as lesion size, number of lesions, enhancement type, and microcalcifications significantly differed across HER2 statuses, except between HER2-zero and -low groups. DM-VBS can predict HER2 status and assist clinicians in making treatment decisions for breast cancer.

This study aimed to compare CT features of COVID-19 and Influenza A pneumonia, develop a diagnostic differential model, and explore a prognostic model for lesion resolution. A total of 446 patients diagnosed with COVID-19 and 80 with Influenza A pneumonitis underwent baseline chest CT evaluation. Logistic regression analysis was conducted after multivariate analysis and the results were presented as nomograms. Machine learning models were also evaluated for their diagnostic performance. Prognostic factors for lesion resolution were analyzed using Cox regression after excluding patients who were lost to follow-up, with a nomogram being created. COVID-19 patients showed more features such as thickening of bronchovascular bundles, crazy paving sign and traction bronchiectasis. Influenza A patients exhibited more features such as consolidation, coarse banding and pleural effusion (P < 0.05). The logistic regression model achieved AUC values of 0.937 (training) and 0.931 (validation). Machine learning models exhibited area under the curve values ranging from 0.8486 to 0.9017. COVID-19 patients showed better lesion resolution. Independent prognostic factors for resolution at baseline included age, sex, lesion distribution, morphology, coarse banding, and widening of the main pulmonary artery. Distinct imaging features can differentiate COVID-19 from Influenza A pneumonia. The logistic discriminative model and each machine - learning network model constructed in this study demonstrated efficacy. The nomogram for the logistic discriminative model exhibited high utility. Patients with COVID-19 may exhibit a better resolution of lesions. Certain baseline characteristics may act as independent prognostic factors for complete resolution of lesions.

More cases of thyroid micro-nodules have been diagnosed annually in recent years because of advancements in diagnostic technologies and increased public health awareness. To explore the application value of various machine learning (ML) algorithms based on dual-layer spectral computed tomography (DLCT) quantitative parameters in distinguishing benign from malignant thyroid micro-nodules. All 338 thyroid micro-nodules (177 malignant micro-nodules and 161 benign micro-nodules) were randomly divided into a training cohort (n = 237) and a testing cohort (n = 101) at a ratio of 7:3. Four typical radiological features and 19 DLCT quantitative parameters in the arterial phase and venous phase were measured. Recursive feature elimination was employed for variable selection. Three ML algorithms-support vector machine (SVM), logistic regression (LR), and naive Bayes (NB)-were implemented to construct predictive models. Predictive performance was evaluated via receiver operating characteristic (ROC) curve analysis. A variable set containing 6 key variables with "one standard error" rules was identified in the SVM model, which performed well in the training and testing cohorts (area under the ROC curve (AUC): 0.924 and 0.931, respectively). A variable set containing 2 key variables was identified in the NB model, which performed well in the training and testing cohorts (AUC: 0.882 and 0.899, respectively). A variable set containing 8 key variables was identified in the LR model, which performed well in the training and testing cohorts (AUC: 0.924 and 0.925, respectively). And nine ML models were developed with varying variable sets (2, 6, or 8 variables), all of which consistently achieved AUC values above 0.85 in the training, cross validation (CV)-Training, CV-Validation, and testing cohorts. Artificial intelligence-based DLCT quantitative parameters are promising for distinguishing benign from malignant thyroid micro-nodules.

Current ultrasound-based screening for endometrial cancer (EC) primarily relies on endometrial thickness (ET) and morphological evaluation, which suffer from low specificity and high interobserver variability. This study aimed to develop and validate an artificial intelligence (AI)-driven diagnostic model to improve diagnostic accuracy and reduce variability. A total of 1,861 consecutive postmenopausal women were enrolled from two centers between April 2021 and April 2024. Super-resolution (SR) technique was applied to enhance image quality before feature extraction. Radiomics features were extracted using Pyradiomics, and deep learning features were derived from convolutional neural network (CNN). Three models were developed: (1) R model: radiomics-based machine learning (ML) algorithms; (2) CNN model: image-based CNN algorithms; (3) DLR model: a hybrid model combining radiomics and deep learning features with ML algorithms. Using endometrium-level regions of interest (ROI), the DLR model achieved the best diagnostic performance, with an area under the receiver operating characteristic curve (AUROC) of 0.893 (95% CI: 0.847-0.932), sensitivity of 0.847 (95% CI: 0.692-0.944), and specificity of 0.810 (95% CI: 0.717-0.910) in the internal testing dataset. Consistent performance was observed in the external testing dataset (AUROC 0.871, sensitivity 0.792, specificity 0.829). The DLR model consistently outperformed both the R and CNN models. Moreover, endometrium-level ROIs yielded better results than uterine-corpus-level ROIs. This study demonstrates the feasibility and clinical value of AI-enhanced ultrasound analysis for EC detection. By integrating radiomics and deep learning features with SR-based image preprocessing, our model improves diagnostic specificity, reduces false positives, and mitigates operator-dependent variability. This non-invasive approach offers a more accurate and reliable tool for EC screening in postmenopausal women. Not applicable.

This study constructed an interpretable machine learning model based on multi-parameter MRI sub-region habitat radiomics and clinicopathological features, aiming to preoperatively evaluate the microsatellite instability (MSI) status of rectal cancer (RC) patients. This retrospective study recruited 291 rectal cancer patients with pathologically confirmed MSI status and randomly divided them into a training cohort and a testing cohort at a ratio of 8:2. First, the K-means method was used for cluster analysis of tumor voxels, and sub-region radiomics features and classical radiomics features were respectively extracted from multi-parameter MRI sequences. Then, the synthetic minority over-sampling technique method was used to balance the sample size, and finally, the features were screened. Prediction models were established using logistic regression based on clinicopathological variables, classical radiomics features, and MSI-related sub-region radiomics features, and the contribution of each feature to the model decision was quantified by the Shapley-Additive-Explanations (SHAP) algorithm. The area under the curve (AUC) of the sub-region radiomics model in the training and testing groups was 0.848 and 0.8, respectively, both better than that of the classical radiomics and clinical models. The combined model performed the best, with AUCs of 0.908 and 0.863 in the training and testing groups, respectively. We developed and validated a robust combined model that integrates clinical variables, classical radiomics features, and sub-region radiomics features to accurately determine the MSI status of RC patients. We visualized the prediction process using SHAP, enabling more effective personalized treatment plans and ultimately improving RC patient survival rates.

This study aims to develop and validate an ultrasoundbased habitat imaging and peritumoral radiomics model for predicting high-risk capsule characteristics for recurrence of pleomorphic adenoma (PA) of the parotid gland while also exploring the optimal range of peritumoral region. Retrospective analysis was conducted on 325 patients (171 in training set, 74 in validation set and 80 in testing set) diagnosed with PA at two medical centers. Univariate and multivariate logistic regression analyses were performed to identify clinical risk factors. The tumor was segmented into four habitat subregions using K-means clustering, with peri-tumor regions expanded at thicknesses of 1/3/5mm. Radiomics features were extracted from intra-tumor, habitat subregions, and peritumoral regions respectively to construct predictive models, integrating three machine learning classifiers: SVM, RandomForest, and XGBoost. Additionally, a combined model was developed by incorporating peritumoral features and clinical factors based on habitat imaging. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). SHAP analysis was employed to improve the interpretability. The RandomForest model in habitat imaging consistently outperformed other models in predictive performance, with AUC values of 0.881, 0.823, and 0.823 for the training set, validation set, and testing set respectively. Incorporating peri-1mm features and clinical factors into the combined model slightly improved its performance, resulting in AUC values of 0.898, 0.833, and 0.829 for each set. The calibration curves and DCA exhibited excellent fit for the combined model while providing great clinical net benefit. The combined model exhibits robust predictive performance in identifying high-risk capsule characteristics for recurrence of PA in the parotid gland. This model may assist in determining optimal surgical margin and assessing patients' prognosis.

To develop a machine learning (ML) model based on clinicopathological and imaging features to predict the Human Epidermal Growth Factor Receptor 2 (HER2) positive expression (HER2-p) of breast cancer (BC), and to compare its performance with that of a logistic regression (LR) model. A total of 2541 consecutive female patients with pathologically confirmed primary breast lesions were enrolled in this study. Based on chronological order, 2034 patients treated between January 2018 and December 2022 were designated as the retrospective development cohort, while 507 patients treated between January 2023 and May 2024 were designated as the prospective validation cohort. The patients were randomly divided into a train cohort (n=1628) and a test cohort (n=406) in an 8:2 ratio within the development cohort. Pretreatment mammography (MG) and breast MRI data, along with clinicopathological features, were recorded. Extreme Gradient Boosting (XGBoost) in combination with Artificial Neural Network (ANN) and multivariate LR analyses were employed to extract features associated with HER2 positivity in BC and to develop an ANN model (using XGBoost features) and an LR model, respectively. The predictive value was assessed using a receiver operating characteristic (ROC) curve. Following the application of Recursive Feature Elimination with Cross-Validation (RFE-CV) for feature dimensionality reduction, the XGBoost algorithm identified tumor size, suspicious calcifications, Ki-67 index, spiculation, and minimum apparent diffusion coefficient (minimum ADC) as key feature subsets indicative of HER2-p in BC. The constructed ANN model consistently outperformed the LR model, achieving the area under the curve (AUC) of 0.853 (95% CI: 0.837-0.872) in the train cohort, 0.821 (95% CI: 0.798-0.853) in the test cohort, and 0.809 (95% CI: 0.776-0.841) in the validation cohort. The ANN model, built using the significant feature subsets identified by the XGBoost algorithm with RFE-CV, demonstrates potential in predicting HER2-p in BC.

To develop and validate a machine learning-based prediction model for the use of multiparametric magnetic resonance imaging(MRI) to predict benign and malignant lesions in the testis. The study retrospectively enrolled 148 patients with pathologically confirmed benign and malignant testicular lesions, dividing them into: training set (n=103) and validation set (n=45). Radiomics characteristics were derived from T2-weighted(T2WI)、contrast-enhanced T1-weighted(CE-T1WI)、diffusion-weighted imaging(DWI) and Apparent diffusion coefficient(ADC) MRI images, followed by feature selection. A machine learning-based combined model was developed by incorporating radiomics scores (rad scores) from the optimal radiomics model along with clinical predictors. Draw the receiver operating characteristic (ROC) curve and use the area under the curve (AUC) to evaluate and compare the predictive performance of each model. The diagnostic efficacy of the various machine learning models was evaluated using the Delong test. Radiomics features were extracted from four sequence-based groups(CE-T1WI+DWI+ADC+T2WI), and the model that combined Logistic Regression(LR) machine learning showed the best performance in the radiomics model. The clinical model identified one independent predictors. The combined clinical-radiomics model showed the best performance, whose AUC value was 0.932(95% confidence intervals(CI)0.868-0.978), sensitivity was 0.875, specificity was 0.871 and accuracy was 0.884 in validation set. The combined clinical-radiomics model can be used as a reliable tool to predict benign and malignant testicular lesions and provide a reference for clinical treatment method decisions.

Lung cancer remains a leading cause of cancer-related deaths worldwide, with accurate classification of lung nodules being critical for early diagnosis. Traditional radiological methods often struggle with high false-positive rates, underscoring the need for advanced diagnostic tools. In this work, we introduce DCSwinB, a novel deep learning-based lung nodule classifier designed to improve the accuracy and efficiency of benign and malignant nodule classification in CT images. Built on the Swin-Tiny Vision Transformer (ViT), DCSwinB incorporates several key innovations: a dual-branch architecture that combines CNNs for local feature extraction and Swin Transformer for global feature extraction, and a Conv-MLP module that enhances connections between adjacent windows to capture long-range dependencies in 3D images. Pretrained on the LUNA16 and LUNA16-K datasets, which consist of annotated CT scans from thousands of patients, DCSwinB was evaluated using ten-fold cross-validation. The model demonstrated superior performance, achieving 90.96% accuracy, 90.56% recall, 89.65% specificity, and an AUC of 0.94, outperforming existing models such as ResNet50 and Swin-T. These results highlight the effectiveness of DCSwinB in enhancing feature representation while optimizing computational efficiency. By improving the accuracy and reliability of lung nodule classification, DCSwinB has the potential to assist radiologists in reducing diagnostic errors, enabling earlier intervention and improved patient outcomes.